Evaluation of the prescribing practice of guideline-directed medical therapy among ambulatory chronic heart failure patients

Table 6 Multivariate binary logistic regression for the use of ACEIs/ARBs, β-blockers, and MRAs in heart failure with preserved ejection fraction (EF > 40) patients

Variables	B	Sig	Exp (B)	95% C.I. for EXP (B)
Variables	B	Sig	Exp (B)	Lower	Upper
ACEIs/ARBs in heart failure with preserved ejection fraction
Hypertension	1.238	.001	3.449	1.677	7.095
CRF	− .686	.036	.504	.266	.955
COPD	.871	.023	2.389	1.129	5.055
Any cognitive impairment	− 1.509	.012	.221	.068	.719
β-blockers in heart failure with preserved ejection fraction
Last clinic HR	− .040	.009	.961	.933	.990
IHD	.740	.023	2.096	1.106	3.971
COPD	− 1.262	.001	.283	.137	.584
GORD	− .681	.043	.506	.262	.980
MRAs in heart failure with preserved ejection fraction
Low standing SBP (BP < 115)	.744	.037	2.105	1.044	4.244

Variable (s) entered on step 1: CRF, any CVA, COPD, any cognitive impairment, gout, and falls. EF, ejection fraction; CRF, chronic renal failure; CVA, cardiovascular accident; COPD, chronic obstructive pulmonary diseases; ACEIs/ARBs, angiotensin converting enzyme inhibitor/angiotensin receptor antagonists. ACEIs/ARBs, angiotensin converting enzyme inhibitor/angiotensin receptor antagonists; MTD, maximum tolerated dose; MRAs, mineralocorticoid receptor blockers. p < .05 is considered significant
Only the significant variables in multivariate analysis are shown

ISSN: 1471-2261